Nav: Home

Oxford strengthens international collaboration to solve epidemic global health problem

December 16, 2015

Two innovative Oxford research programmes will explore the relationship between metabolism and inflammation in metabolic diseases. Obesity, insulin resistance, type 2 diabetes (T2D) and associated cardiovascular disease (CVD) -- all metabolic diseases -- are an epidemic global health problem.

Obesity, insulin resistance, type 2 diabetes (T2D) and associated cardiovascular disease (CVD) -- all metabolic diseases -- are an epidemic global health problem.

With almost 400 million people worldwide suffering from T2D and total deaths from the condition due to rise by more than 50% in the next 10 years, research which addresses the causes of these diseases and delivers effective treatment for them is of paramount importance. So two Oxford teams are beginning research programmes, funded by the Novo Nordisk Foundation.

The Immunometabolism Research Programme led by Professor Claudia Monaco aims to deliver fundamental knowledge about inflammation in metabolic diseases, as well as identify effective solutions for new medications and prevention strategies.

Metabolism denotes the processes by which the body gets or makes energy from food and store it in adipose tissue for release upon demand. In metabolic diseases such as T2D and CVD these processes are disturbed.

Metabolic diseases are associated with inflammation but little is known about this relationship. Inflammation in these conditions differs from other types of inflammation in that it is sustained and of low grade, which blurs typical patterns of disease and makes it a very difficult subject to study.

The project, which is due to start in May 2016, will focus on discovering new pathways -- series of reactions within cells -- and molecules that are important in detecting alterations in metabolism, as well as understanding how immune cells work in metabolic diseases.

Professor Claudia Monaco said: 'This is a huge opportunity to explore inflammation in the metabolic process, in an innovative way. Current treatments for metabolic diseases target the metabolic side of the conditions, addressing the symptoms but leaving the causes largely untreated -- we want to close this gap. With the support of Novo Nordisk Foundation, our project brings together people with key skills working to solve this urgent health puzzle, focusing on the inflammation aspect of disease to deliver intelligent drug design and new solutions which really impact on disease.'

Meanwhile, Professor Robin Choudhury will lead a project going from big data analysis to find a causal relationship between inflammatory factors and the development of type 2 diabetes and related disorders, to analysis of molecular and cellular mechanisms, to intervention studies.

Professor Choudhury says: 'The goal of the programme is to revise the way we regard diabetes spectrum diseases by learning more about the role of inflammation in the pathogenesis of the disease and, in particular, the vascular complications. If successful we may open up new therapeutic possibilities that go beyond merely treating blood sugar and instead target biologically relevant pathways and processes.'

Together, the two projects have received DKK 80 million (GBP 7.8 million/ USD 11.7 million) of funding from the Novo Nordisk Foundation to bring together 24 experts in the fields of metabolism and inflammation from Oxford, the University of Copenhagen, Denmark, and the Karolinska Institutet in Sweden.
-end-


University of Oxford

Related Diabetes Articles:

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
More Diabetes News and Diabetes Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...